A practical reference on Reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
=== Mechanism of action === Oclacitinib is not a corticosteroid or antihistamine, but rather modulates the production of signal molecules called cytokines in some cells. Normally, a cytokine binds to a JAK (Janus kinase) receptor, driving the two individual chains to come together and self-phosphorylate. This brings in STAT proteins, which are activated and then go to the nucleus to increase transcription of genes coding for cytokines, thus increasing cytokine production. Oclacitinib inhibits signal JAK family members (JAK1, JAK2, JAK3, and tyrosine kinase 2), most effectively JAK1, while not significantly inhibiting non-JAK kinases.
An official independence referendum happens later in December August 25: Belarus declares independence from the Soviet Union. August 27: Moldova declares independence from the Soviet Union. August 31: Uzbekistan and Kyrgyzstan declare independence from the Soviet Union. September: 1991 Zaire unrest occurred. September 7: Macedonia holds an independence referendum with a majority voting in favor of independence. September 9: Tajikistan declares independence from the Soviet Union. September 21: Armenia holds an independence referendum with a majority voting for independence from the Soviet Union despite declaring independence in August 1990. October 26: Turkmenistan holds an independence referendum with a majority voting for independence from the Soviet Union. October 27: Turkmenistan declares its independence from the Soviet Union. October 31: The Djiboutian Civil War begins. November 1: Chechnya declares sovereignty. November 12: The Indonesian Army massacred at least 250 East Timorese pro-independence protesters during the Indonesian occupation of East Timor. December 1: Ukraine holds an independence referendum with a majority voting in favor of independence. December 16: Kazakhstan declares its full independence from the Soviet Union. December 22: The Georgian Civil War begins. December 25: Mikhail Gorbachev resigns as President of the USSR. The flag of the Soviet Union is lowered for the last time over the Kremlin and is later replaced by the Russian flag. Also that day U.S. President George H. W.
==== Poverty ==== The U.S. Census Bureau's Statistical Abstract of the United States: 2012 ranks Detroit first among all 71 U.S. cities for which rates were calculated in percentage of the city's population living below the poverty level. The individual rate living below the poverty level is 36.4%; the family rate is 31.3%.
==== Specimen storage and stability ==== Blood specimens for complete blood count (CBC) analysis should ideally be analysed as soon as possible after collection to minimise pre-analytical changes. When delays are unavoidable, EDTA-anticoagulated blood may be stored under refrigerated conditions (2–8 °C), although the stability of individual CBC parameters varies. Haemoglobin concentration and red blood cell and white blood cell counts are generally more stable during refrigerated storage than platelet-related parameters and some red blood cell indices. Laboratories should follow validated storage recommendations and consider potential analytical changes when interpreting delayed specimens. Blood tests are also used to identify autoimmune diseases and Immunoglobulin E-mediated food allergies (see also Radioallergosorbent test).
Sources: en.wikipedia.org
== Contraindications == Tapentadol is contraindicated in people with epilepsy or who are otherwise prone to seizures. It raises intracranial pressure so should not be used in people with head injuries, brain tumors, or other conditions which increase intracranial pressure. It increases the risk of respiratory depression so should not be used in people with asthma. As with other μ-opioid agonists, tapentadol may cause spasms of the sphincter of Oddi, and is therefore discouraged for use in patients with biliary tract disease such as both acute and chronic pancreatitis. People who are rapid or ultra rapid metabolizers for the CYP2C9, CYP2C19, and CYP2D6 enzymes may not respond adequately to tapentadol therapy. Due to reduced clearance, tapentadol should be administered with caution to people with moderate liver disease and not at all in people with severe liver disease.
the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD L1 with a combined positive score (CPS) ≥ 10 as monotherapy. the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumors express PD-L1 with a CPS ≥ 1 as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy. the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumors express PD-L1 with a ≥ 50% TPS and progressing on or after platinum-containing chemotherapy as monotherapy. the first-line treatment of advanced renal cell carcinoma in adults in combination with axitinib. In June 2020, the US FDA approved an indication for pembrolizumab as the first-line treatment for people with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. The approval marks the first immunotherapy approved for that population in the US as a first-line treatment and which is administered to people without also giving chemotherapy. In March 2021, the US FDA approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy to treat metastatic or locally advanced esophageal or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma in people who are not candidates for surgical resection or definitive chemoradiation.
The player's main method of defeating guests is with Combat pages, items used to attack and defend in combat through predetermined actions. The number of Combat Pages usable in a single Scene is equal to the number of Speed Dice a character has. Attacks deal both physical and stagger damage, affecting characters' HP and SR respectively. If a character's SR reaches zero, they will be unable to move and receive fatal damage from all attacks until their SR resets the next turn. A character dies (for the ongoing reception) if their HP reaches 0. Upon starting the Scene, all characters' Speed dice will randomly roll a low or high number or value, determining its Speed and the order of characters' actions. Librarians can redirect Combat pages towards them if they possess higher Speed than their target. Most characters (except bosses) start a reception with 1 or 2 Speed dice. If a librarian redirects a Combat page or opposes a Combat page directed at them, they enter a clash where both sides' Combat pages' actions interact with each other. Two dice will roll and the highest value will act; if both dice roll the same value, actions will be canceled out. Else, the attack counts as a one-sided action where attacks are not opposed. The player needs to carefully manage available resources, namely 'Light' (a form of combat stamina) and Combat pages, which return into the deck to be randomly picked upon usage. If the librarian's current Light is lower than the cost of any available Combat page, or if the librarian has no Combat pages to initiate action, they will be unable to act.
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.